[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iliac-aneurysm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iliac-aneurysm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,80,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100593338","ihub-stent-graft-for-iliac-artery-aneurysms-safety-performance-and-effectiveness-study-100593338",false,"NCT07005141","iHub Stent-Graft for Iliac Artery Aneurysms: Safety, Performance, and Effectiveness Study","iHub no Tratamento de Aneurismas ilíacos: Avaliação da Segurança, Desempenho e Eficácia.","TriHub","Inclusion Criteria: Sign the Informed Consent Form (ICF); Are ≥ 18 years of age;\n\nMeet at least one of the following criteria for iliac artery aneurysm:\n\n1. Common iliac artery aneurysm ≥ 25 mm in diameter;\n2. Aneurysm growth of 5 mm or more within the last six months;\n3. Maximum aneurysm diameter exceeds 1 to 1.5 times the normal arterial segment diameter, that is ≥ 25 mm maximum diameter;\n4. Saccular aneurysm greater than 20 mm;\n5. Abdominal aortic aneurysm with extension into the common iliac arteries of less than 20 mm;\n\nHave a previously implanted aorto-bi-iliac stent-graft with branch diameter between 14 and 16 mm;\n\nHave iliac\u002Ffemoral access vessel morphology compatible with vascular access techniques, placement systems, devices, and\u002For accessories;\n\nAre classified as ASA physical status I to III. ASA IV patients may be included if their life expectancy is greater than one year;\n\nAre able and willing to comply with follow-up requirements during the 360-day post-implant period.\n\n\\-\n\nExclusion Criteria: Pregnant women, women of childbearing potential, or breastfeeding women;\n\nA dissection, rupture, or complex vascular lesion due to trauma;\n\nNeed for emergency surgery;\n\nContraindication to angiography;\n\nDiffuse atherosclerotic disease in any common iliac artery reducing its diameter to \\\u003C 4 mm;\n\nCongenital abnormalities where stent placement would obstruct a major artery. Such abnormalities must be assessed prior to treatment;\n\nUnstable angina;\n\nClass III obesity (BMI ≥ 40 kg\u002Fm²) or other clinical conditions that severely limit radiographic visualization of the aorta;\n\nConnective tissue disease (e.g., Marfan or Ehlers-Danlos syndrome);\n\nHypercoagulable state;\n\nContraindication to anticoagulation therapy;\n\nAcute or chronic renal insufficiency (serum creatinine \\> 2.0 mg\u002FdL);\n\nLife expectancy of less than one year;\n\nPresence of a systemic infection that could increase the risk of endovascular device infection;\n\nKnown sensitivity or allergy to device materials: expanded polytetrafluoroethylene (ePTFE), fluorinated ethylene propylene (FEP), or nickel-titanium (Nitinol).\n\n\\-","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the safety, performance, and Preliminary effectiveness of the iHub endoprosthesis system in treating iliac artery aneurysms in adult patients requiring endovascular repair. The study population includes both male and female adults over 18 years of age who meet the inclusion criteria for endovascular treatment of iliac artery aneurysms.\n\nThe main questions it aims to answer are:\n\nIs the iHub stent-graft system safe for use in patients with iliac artery aneurysms? Does the iHub system demonstrate adequate technical performance and sustained patency over a 12-month follow-up period? Participants will undergo a minimally invasive endovascular procedure to implant the iHub endoprosthesis system. The device is designed to preserve internal iliac artery flow while excluding the aneurysmal segment.\n\nParticipants will:\n\nUndergo pre-screening evaluations including clinical examination, laboratory tests, and imaging (CT angiography and ultrasound).\n\nUndergo endovascular implantation of the iHub device. Attend follow-up visits at 30, 90, 180, and 360 days post-implant to assess clinical outcomes and device performance.",[27,28],"Iliac Aneurysm","Aortic Aneurysm, Abdominal",[30,31,32,33,34,35],"iliac aneurysm","iHub","stentgraft system","endovascular treatment","abdominal aortic aneurysm","EVAR","RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":40},"2026-05-26",{"date":44,"type":21},"2028-12",{"name":46,"class":47},"Archo Medical S.A","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100626085","fast-track-protocol-for-endovascular-aneurysm-repair-evar-of-infrarenal-abdominal-aortic-aneurysms-100626085","NCT07431047","Fast-Track Protocol for Endovascular Aneurysm Repair (EVAR) of Infrarenal Abdominal Aortic Aneurysms","Fast-Track Protocol for Infrarenal EVAR","Inclusion criteria\n\n* Patient diagnosed with infrarenal Abdominal Aortic Aneurysm (AAA) indicated for elective endovascular repair.\n* Patient diagnosed with Penetrating Aortic Ulcer (PAU) indicated for elective endovascular repair.\n* Patient resident in the Bologna metropolitan area OR able to remain within the area for at least 7 days post-procedure.\n* Patient with a cohabitant or caregiver available (cannot live alone) to ensure safety during the early post-discharge phase.\n* Signed informed consent specifically for local\u002Flocoregional anesthesia, the procedure and the specific fast-track pathway.\n* Common femoral arteries diameter \\> 7 mm\n* Common femoral arteries free of severe calcification (\\\u003C 50% of vessel circumference), suitable for percutaneous closure device\n* Proximal aortic neck length \\> 15 mm\n* Proximal aortic neck diameter \\\u003C 30 mm\n* Proximal aortic neck without severe angulation (\\\u003C60°) or circumferential thrombus \\\u003C50%\n\nExclusion Criteria:\n\n* Patient resident outside the Bologna metropolitan area or unable to remain within the area for at least 7 days post-procedure.\n* Patient without a cohabitant or caregiver available\n* Common femoral arteries diameter \\\u003C7 mm\n* Common femoral arteries with severe calcification (\\> 50% of vessel circumference), unsuitable for percutaneous closure device\n* Proximal aortic neck length \\\u003C 15 mm\n* Proximal aortic neck diameter \\> 30 mm\n* Proximal aortic neck with severe angulation (\\>60°) or circumferential thrombus \\>50%\n* General anesthesia\n* Open conversion\n* Medical contraindication to local\u002Flocoregional anesthesia or patient refusal\u002Finability to cooperate during the procedure.\n* Severe Chronic Kidney Disease (glomerular filtration rate \\> 30 ml\u002Fmin) requiring exclusively CO2 angiography\n* Ruptured or symptomatic aneurysms requiring emergency repair.\n* Clinical condition requiring intensive invasive monitoring (e.g., CVC, urinary catheter) prior to the procedure.",{"count":57,"type":21},50,"1 Year","OBSERVATIONAL","The study aims to evaluate the clinical and economic efficacy of a \"Fast-Track\" protocol for the elective endovascular treatment (EVAR) of infrarenal abdominal aortic aneurysms (AAA). The protocol minimizes invasiveness through the use of local\u002Flocoregional anesthesia, a total percutaneous approach, and the avoidance of routine Intensive Care Unit (ICU) admission. The primary goal is to reduce hospital Length of Stay (LOS) to \\\u003C48 hours and decrease procedural costs, while maintaining safety and increasing patient turnover compared to the standard of care.",[62,63,64,27],"Abdominal Aortic Aneurysm","Infrarenal Abdominal Aortic Aneurysm","Penetrating Aortic Ulcers (PAUs)",[35,66,67,68,69],"Fast-track Surgery","Local Anesthesia","Percutaneous Access","Cost-Benefit Analysis","NOT_YET_RECRUITING","2026-02-20",{"date":73,"type":40},"2026-02-24",{"date":75,"type":21},"2026-02-11",{"date":77,"type":21},"2027-12-31",{"name":79,"class":47},"University of Bologna",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100588821","campania-puglia-branch-iliaco-100588821","NCT06946381","CAMpania PugliA bRanch Iliaco","CAMPARI","Inclusion Criteria:\n\n* An aortoiliac or aortic aneurysm of surgical interest based on the most recent local guidelines treated with the E-liac stent-graft system, alone or in combination with other devices\n\nExclusion Criteria:\n\n* Patient's refusal to be enrolled in the registry\n* Patient treated with devices not including the E-liac stent-graft system",{"count":88,"type":21},200,"Spontaneus Multicentric Observational registry to investigate the medium and long-term performances of the Iliac E-liac Branch Device from Artivion for treatment of Aortoiliac aneurysms in a real-world consecutive patients cohort.",[91,27],"Aortoiliac Aneurysm",[93,94,95],"evar","bevar","AAA","2025-04-23",{"date":98,"type":40},"2025-04-27",{"date":100,"type":40},"2015-01-01",{"date":102,"type":21},"2028-01-01",{"name":104,"class":47},"Federico II University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":115,"conditions":116,"keywords":117,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100528553","an-exploratory-study-of-iliac-artery-branch-stent-for-internal-iliac-artery-reconstruction-in-abdominal-aortic-aneurysmiliac-aneurysm-repair-100528553","NCT06162273","An Exploratory Study of Iliac Artery Branch Stent for Internal Iliac Artery Reconstruction in Abdominal Aortic Aneurysm\u002FIliac Aneurysm Repair","Comparing the Efficacy and Safety of IBD Stent of Shenzhen Xianjian Company and IBE Stent of American Gore Company for Reconstruction of Internal Iliac Artery in Abdominal Aortic Aneurysm\u002FIliac Aneurysm Repair","Inclusion Criteria:\n\n1. Patients with iliac aneurysms combined with or without abdominal aortic aneurysms and internal iliac arteries reconstructed with iliac branch stents;\n2. Male or female ≥18 years old, ≤85 years old;\n3. Life expectancy \\> 2 years;\n4. The patient signed the informed consent voluntarily and was able to comply with the treatment plan and complete the follow-up and examination as planned.\n\nExclusion Criteria:\n\n1. Fungal or ruptured aneurysm\n2. Known complications of thoracic aortic aneurysm require interventional treatment\n3. American Association of Anesthesiologists (ASA) Grade V\n4. Creatinine \\> 2.5mg\u002FdL or dialysis patients\n5. NYHA Grade IV heart failure\n6. Intercalation, severe calcification, or anchoring area with thrombosis\n7. Severe curvature or narrowing of the iliac and\u002For femoral arteries, resulting in difficulty in stent delivery\n8. Conduct another device or drug study within 1 year of treatment\n9. Systemic infection\n10. Combined with connective tissue disease\n11. Known history of drug use\n12. Known allergies or allergies to equipment materials","85 Years",{"count":114,"type":21},40,"The purpose of this study is to evaluate the efficacy and safety of IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company in the treatment of abdominal aortic aneurysm\u002Filiac aneurysm reconstruction of internal iliac artery",[28,27],[118,119,120],"Iliac artery branch stent","Patency rate","Internal iliac artery","2023-12-01",{"date":123,"type":40},"2023-12-08",{"date":121,"type":21},{"date":126,"type":21},"2026-12-01",{"name":128,"class":47},"RenJi Hospital",1]